Actively Recruiting
Phase 11b Trial of AMG 436 Alone and With Other Therapies in Patients With MSI-HdMMR Solid Tumors
Led by Amgen · Updated on 2026-10-20
464
Participants Needed
27
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying AMG 436 in participants with metastatic or locally advanced solid tumors that have microsatellite instability-high MSI-H or mismatch repair deficiency dMMR. The trial aims to evaluate the safety profile of AMG 436 and to identify the maximum tolerated dose or recommended dose when given alone or combined with other anti-cancer treatments. This Phase 11b study focuses on understanding how AMG 436 works in these specific tumor types. Participants will receive AMG 436 either as a single agent or combined with chemotherapy in various dose escalation and expansion phases. Some participants in the United States will receive AMG 436 under both fasted and fed conditions to assess potential food effects. The study includes multiple parts monotherapy dose escalation, combination dose escalation, monotherapy dose expansion and optimization, and combination dose expansions with chemotherapy. During the trial, participants will undergo regular safety and treatment monitoring for up to five years, including the assessment of dose-limiting toxicities and treatment-emergent adverse events. Researchers will also measure blood levels of AMG 436, tumor response according to standardized criteria, and other pharmacokinetic and pharmacodynamic markers. Follow-up evaluations will continue to monitor overall survival, disease progression, and treatment response duration.
CONDITIONS
Brief Title
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here